Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...

This has demonstrated the potential of palbociclib in treating Alzheimer’s disease,” Chen said. The research shows the drug ...

If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The ...

A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

The Office of the Inspector General reviewed the FDA’s use of accelerated approval for 24 drugs, ultimately finding issues ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

Anavex Life Sciences is back with more data for a pill that it’s looking to get approved in a variety of neurodegenerative ...

With an aging global population, rates of Alzheimer’s disease on the rise, high costs of care for those with dementia, and an unpromising landscape for effective drugs, questions of how to prevent or ...

“There are things that we can do at all stages of our lives deliberately,” says Prof Schott. “It’s never too early to start ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according to a report. The report by GlobalData, a data and analytics company, showed ...